NewsFriday, 08. February 2013
Lung deposition in children
Inhalation therapy is the cornerstone of the management of many respiratory diseases. Therefore the particle size is one of the most important device related factor for drug deposition in the lower airways. Especially in young children, particle size should be optimized for the deposition in the smaller diameter airways.
A current study assessed the impact of different particle sizes of a nebulised aerosol aerosol
An aerosol is a colloid of fine solid particles or liquid droplets, in air or another gas. in children with cystic fibrosis cystic fibrosis
Genetic disorder that affects most critically the lungs, leading to thick, viscous secretions. (CF) via two tested nebulisers, the LC SPRINT Junior and the LC SPRINT STAR connected to a PARI BOY SX compressor (PARI GmbH, Germany).
Table 1: Volume median diameter and (GSD) of LC SPRINT Junior and LC SPRINT STAR .
Eight children between 4-8 years with stable cystic fibrosis cystic fibrosis
Genetic disorder that affects most critically the lungs, leading to thick, viscous secretions. underwent nebulisation with the two tested nebulisers in a randomized, cross-over manner, on separate occasions at least 7 days apart. Scinthigraphic scans were taken immediately after nebulisation was completed.
Lung deposition (% of nebuliser fill dose) was 13.2% for the LC SPRINT Junior and 14.4% for the LC SPRINT STAR.
No significant difference in total lung deposition due to similar volume median diameter of the two tested nebulisers LC SPRINT Junior (VMD 2.9 µm; GSD 2.7) and LC SPRINT STAR (VMD 2.5 µm; GSD 2.6).
Comparable mean nebulisation times of 7.3 vs. 7.6 minutes for LC SPRINT Junior vs. LC SPRINT STAR.
Table 2: Comparison of lung deposition results in children (standard deviation): 13.2% (4.8) and 14.4% (6.9) for LC SPRINT Junior and LC SPRINT STAR.
Both PARI nebulisers showed excellent scinthigraphic lung deposition data in children aged 4-8 years.
Choosing high efficient nebulisers like PARI LC SPRINT STAR and Junior, that are specially adapted to the needs of small patients, can be regarded as a crucial factor for a successful treatment with therapeutic aerosols in infants.
 Devadason S.; December 2012; Abstract booklet, DDL congress, Edinburgh